IntraBio is developing drug candidates that have broad applicability to rare and common neurological and inflammatory diseases.
IntraBio’s leading compounds are a series of orally administered, modified amino-acid analogs that are well tolerated and have an excellent safety profile. These compounds have been observed to have significant efficacy in the treatment of rare lysosomal storage disorders and common neurodegenerative diseases in Phase II observational clinical studies.
Based on the promising findings, IntraBio is in the process of applying for multinational, randomized, placebo-controlled clinical trials for the treatment of patients with NPC, Tay-Sachs disease, and subtypes of Cerebellar Ataxia. IntraBio intends to have multiple clinical sites in Europe and the U.S. and commence enrollment in 2018.NEWS
IntraBio will provide full details of its clinical programs, including enrollment and inclusion criteria for upcoming clinical trials, as soon as they become available. Patient organizations in both the EU and US will be regularly updated to announcements from IntraBio. All official announcements or statements will also be highlighted in the News section of our website.
If you are interested in more information about IntraBio’s clinical programs and would like to receive updates regarding upcoming clinical trials, please get in touch here.News